Global S&T Development Trend Analysis Platform of Resources and Environment
Investment in innovations to transform patient outcomes | |
admin | |
2019-03-22 | |
发布年 | 2019 |
语种 | 英语 |
国家 | 英国 |
领域 | 气候变化 |
正文(英文) | 22/03/2019 ![]() Cutting edge health projects, including new software which enables radiologists to diagnose breast cancer more effectively and gene therapy to combat kidney disease, have received £23 million of government funding, it was announced today. The funding has been awarded under the Biomedical Catalyst programme jointly run by the UK’s innovation agency, Innovate UK and the Medical Research Council, both part of UK Research and Innovation. Announcing the funding, Life Sciences Minister Lord Henley, said: “From new software to diagnose breast cancer to improved gene therapies for children with leukaemia, these projects show the life-changing effect UK research can have. “The Biomedical Catalyst programme demonstrates our modern Industrial Strategy in action; supporting businesses to develop innovative products and creating the high-skilled jobs of the future whilst improving the lives of people throughout the country.” Dr Kath Mackay, Interim Director - Ageing Society, Health & Nutrition, Innovate UK added: “Increasingly, new technologies and treatments are able to address debilitating and chronic conditions that are hard to treat. By continuing to invest in innovation through programmes such as the Biomedical Catalyst, we can continue to transform outcomes for patients and support and grow the UK’s world-leading health sector.” Nine early stage projects have received total funding of almost £7.5 million. These include:
Fifteen feasibility projects have received total funding of just over £2 million. These include:
In the latest round of awards, the MRC committed almost £13.5 million funding to BMC projects, including:
The MRC supports academically-led translational research under the auspices of the BMC through its Confidence in Concept and Developmental Pathway Funding Scheme (DPFS) schemes. Dr Louise Jones, head of translational research at the MRC, said: “These latest projects are further demonstration of the world-leading science coming out of the vibrant academic and industrial research base of the UK. The success of the Catalyst’s funding schemes shows the value of dedicated support in the development of therapies, diagnostics and devices that will benefit both patients and the UK economy.” Notes for editorsThe Biomedical Catalyst is a unique partnership between the MRC and Innovate UK, providing responsive and effective support to the most innovative life sciences opportunities to accelerate the progress of novel products toward patient benefit. The aim of the Biomedical Catalyst is to support the development of innovative healthcare products, technologies and processes. These can include (but are not limited to):
SMEs can apply for a share of up to £8 million to continue a project's early stage development and technical evaluation, up to readiness for clinical testing. The Biomedical Catalyst was established in 2012 to achieve 3 key objectives:
The programme provides funding to help UK SMEs speed up bringing new products to market and secure onward investment. The programme is run by Innovate UK and the Medical Research Council. Please sign up to our weekly newsletter to keep up to date: Share: |
URL | 查看原文 |
来源平台 | UK Research and Innovation (Research Councils UK) |
文献类型 | 新闻 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/102995 |
专题 | 气候变化 |
推荐引用方式 GB/T 7714 | admin. Investment in innovations to transform patient outcomes. 2019. |
条目包含的文件 | 条目无相关文件。 |
个性服务 |
推荐该条目 |
保存到收藏夹 |
查看访问统计 |
导出为Endnote文件 |
谷歌学术 |
谷歌学术中相似的文章 |
[admin]的文章 |
百度学术 |
百度学术中相似的文章 |
[admin]的文章 |
必应学术 |
必应学术中相似的文章 |
[admin]的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论